KL
Lauper, Kim
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Reply | Arthritis & rheumatology | 2025 | 10 | 0 | |||
| From forgotten to frontline : the new era of crystal diseases ? | ARP rheumatology | 2025 | 28 | 57 | |||
| Défis dans la prise en charge des arthrites microcristallines | Revue médicale suisse | 2025 | 17 | 0 | |||
| Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study) | Arthritis & rheumatology | 2025 | 82 | 53 | |||
| Trends and influences in women authorship in randomised controlled trials in rheumatology : a comprehensive analysis of all published RCTs from 2009 to 2023 | RMD open | 2025 | 47 | 32 | |||
| Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer | Annals of the rheumatic diseases | 2025 | 45 | 0 | |||
| Rhumatologie : ce qui a changé en 2023 | Revue médicale suisse | 2024 | 52 | 35 | |||
| Rhumatologie en crise : repenser la formation et les soins face à un défi croissant | Revue médicale suisse | 2024 | 32 | 43 | |||
| Large language models for accurate disease detection in electronic health records : the examples of crystal arthropathies | RMD open | 2024 | 29 | 71 | |||
| Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study) | Annals of the rheumatic diseases | 2024 | 96 | 79 | |||
| Development and validation of a self-updating gout register from electronic health records data | RMD open | 2024 | 100 | 141 | |||
| A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs : Establishing a Framework to Create a "Safety Checklist" | Drug safety | 2024 | 27 | 0 | |||
| Douleur monoarticulaire aiguë non traumatique | Revue médicale suisse | 2024 | 75 | 0 | |||
| Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs : does line of therapy matter ? | Rheumatology | 2024 | 29 | 90 | |||
| Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces : results from an international survey | RMD open | 2024 | 37 | 44 | |||
| Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA | BMJ open | 2024 | 135 | 109 | |||
| Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies | Joint bone spine | 2024 | 101 | 101 | |||
| 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer | Annals of the rheumatic diseases | 2024 | 56 | 606 | |||
| Polyarthrite rhumatoïde | Revue médicale suisse | 2024 | 47 | 29 | |||
| Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort study | Frontiers in medicine | 2023 | 67 | 88 | |||
| Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab | RMD open | 2023 | 84 | 30 | |||
| A potential role for chlamydial infection in rheumatoid arthritis development | Rheumatology | 2023 | 92 | 178 | |||
| Use of complementary medicine and its association with SARS-CoV-2 vaccination during the COVID-19 pandemic : a longitudinal cohort study | Swiss medical weekly | 2023 | 56 | 106 | |||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update | Annals of the rheumatic diseases | 2023 | 258 | 250 | |||
| The longitudinal study of subjective wellbeing and absenteeism of healthcare workers considering post-COVID condition and the COVID-19 pandemic toll | Scientific reports | 2023 | 150 | 36 | |||
| Treatment for rheumatoid arthritis: Insights from real-life data | 2023 | 141 | 52 | ||||
| Poussées de la polyarthrite rhumatoïde | Revue médicale suisse | 2023 | 101 | 72 | |||
| Prise en charge hospitalière de la goutte | Revue médicale suisse | 2023 | 32 | 123 | |||
| Rhumatologie : ce qui a changé en 2022 | Revue médicale suisse | 2023 | 151 | 88 | |||
| Prevalence of Post-COVID Condition 12 Weeks After Omicron Infection Compared With Negative Controls and Association With Vaccination Status | Clinical infectious diseases | 2023 | 170 | 200 | |||
| Omicron-specific cytotoxic t-cell responses after a third dose of mrna covid-19 vaccine among patients with multiple sclerosis treated with ocrelizumab | JAMA neurology | 2022 | 244 | 163 | |||
| EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology | Annals of the rheumatic diseases | 2022 | 209 | 78 | |||
| One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals | Journal of internal medicine | 2022 | 270 | 109 | |||
| After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries | Annals of the rheumatic diseases | 2022 | 266 | 428 | |||
| Nouveautés en médecine 2021 - Rhumatologie | Revue médicale suisse | 2022 | 295 | 228 | |||
| Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study | Annals of the rheumatic diseases | 2022 | 293 | 114 | |||
| 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases | Annals of the rheumatic diseases | 2022 | 121 | 1,997 | |||
| Prévention vaccinale chez les patients avec des maladies rhumatismales | Revue médicale suisse | 2022 | 110 | 111 | |||
| Global epidemiology of rheumatoid arthritis | Nature reviews. Rheumatology | 2022 | 354 | 1 | |||
| Extent of and reasons for discontinuation and nonpublication of interventional trials on connective tissue diseases: an observational study | Arthritis care & research | 2022 | 268 | 264 | |||
| Robust T-Cell Responses in Anti-CD20 Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study | Clinical infectious diseases | 2022 | 232 | 59 | |||
| Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration | Annals of the rheumatic diseases | 2022 | 339 | 98 | |||
| Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases | Frontiers in immunology | 2022 | 204 | 81 | |||
| The pandemic toll and post-acute sequelae of SARS-CoV-2 in healthcare workers at a Swiss University Hospital | Preventive medicine reports | 2022 | 252 | 115 | |||
| The chronification of post-COVID condition associated with neurocognitive symptoms, functional impairment and increased healthcare utilization | Scientific reports | 2022 | 220 | 100 | |||
| Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the eustar database | Rheumatology | 2021 | 269 | 362 | |||
| Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis | BMJ Open | 2021 | 354 | 170 | |||
| How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies | Expert review of clinical immunology | 2021 | 167 | 290 | |||
| Publishing in 2@84 | Annals of the Rheumatic Diseases | 2021 | 190 | 0 | |||
| Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology | RMD open | 2021 | 264 | 151 | |||
| EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future | RMD open | 2021 | 225 | 154 | |||
| Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic | Annals of the Rheumatic Diseases | 2021 | 208 | 298 | |||
| The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries | Rheumatology | 2021 | 244 | 0 | |||
| The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus | Autoimmunity Reviews | 2021 | 241 | 0 | |||
| Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab | RMD open | 2021 | 262 | 110 | |||
| Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study | RMD Open | 2020 | 312 | 173 | |||
| Back pain occurrence and treatment-seeking behavior among nurses: the role of work-related emotional burden | Quality of Life Research | 2020 | 372 | 1 | |||
| Petites molécules dans la polyarthrite rhumatoïde | Revue médicale suisse | 2020 | 291 | 3 | |||
| Response to: 'When binary and continuous responses disagree' by Dr Ouyang | Annals of the Rheumatic Diseases | 2020 | 320 | 2 | |||
| Predictive factors of treatment persistence in rheumatoid arthritis | Joint, Bone, Spine | 2020 | 422 | 649 | |||
| Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution | Rheumatology | 2019 | 371 | 0 | |||
| Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? | RMD Open | 2019 | 334 | 150 | |||
| Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis | Seminars in Arthritis and Rheumatism | 2019 | 320 | 232 | |||
| Associations of regrets and coping strategies with job satisfaction and turnover intention: international prospective cohort study of novice healthcare professionals | Swiss Medical Weekly | 2019 | 434 | 465 | |||
| Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration | Annals of the Rheumatic Diseases | 2018 | 457 | 1 | |||
| Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries | RMD Open | 2018 | 352 | 178 | |||
| Le risque cardiovasculaire dans la polyarthrite rhumatoïde, la spondylarthrite axiale et le rhumatisme psoriasique | 2018 | 788 | 477 | ||||
| Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis | Arthritis Care and Research | 2018 | 436 | 438 | |||
| The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis | Clinical Rheumatology | 2017 | 630 | 3 | |||
| Cardiovascular risk in patients with rheumatoid arthritis | Seminars in Immunopathology | 2017 | 458 | 0 | |||
| Traitement de fond de la polyarthrite rhumatoïde | Revue médicale suisse | 2014 | 292 | 2 | |||
| Hépatite auto-immune | Revue médicale suisse | 2013 | 318 | 1 |
